We had previously reported on a presentation by Calais et al. earlier this year. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: Axumin, fluciclovine, fluorine-18, gallium-68, imaging, PET/CT, PSMA, scan | 9 Comments »
Early data suggest 18F-DCFPyL PET/CT scans can change patient management
Posted on April 24, 2019 by Sitemaster
A media release issued yesterday by Progenics Pharmaceuticals states that the investigational imaging agent 18F-DCFPyL changed physician behavior in the management of biochemically recurrent prostate cancer in > 65 percent of patients. … READ MORE …
Filed under: Uncategorized | Tagged: 18F-DCFPyL, biochemical, change, CT, imaging, Management, PET, recurrence, scan | Leave a comment »
Progenics reports outcome of OSPREY 2301 trial of PyL™
Posted on October 5, 2018 by Sitemaster
In a media release issued earlier this morning, Progenics Pharmaceuticals has announced the outcome of a Phase II/III trial of their proprietary, PSMA-targeted imaging agent PyL (also known as 18F-DCFPyL) for identification of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: 18F-DCFPyL, imaging, PET, PSMA, PyL | 8 Comments »
Trial of new imaging agent nears completion
Posted on June 26, 2018 by Sitemaster
Early this morning, Progenics Pharmaceuticals announced completion of enrollment of patients in the Phase II/III OSPREY trial of a new PSMA-targeted PET/CT imaging agent for detection of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: imaging, OSPREY, Progenics, PSMA, PyL | 1 Comment »
Two leading women talk about the future of treatment of advanced prostate cancer
Posted on April 4, 2018 by Sitemaster
Nearly 30 years ago, when your sitemaster first attended a prostate cancer meeting (in 1989) related to the upcoming approval of a new drug called flutamide, he doesn’t remember there being a single clinician at the meeting who was female — out of the 150 or so urologists and medical oncologists who had been invited. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: advanced, Diagnosis, future, imaging, research, Treatment | 6 Comments »
Copper-64 PET/CT scanning for biochemically relapsing prostate cancer
Posted on March 6, 2018 by Sitemaster
A group of Italian researchers have apparently shown that a copper-64 dichloride-based radiotracing agent (64CuCl2) is better than currently-used 18FCl radiotracers in the detection of biochemically recurrent prostate cancer with PET/CT scans … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: copper-64, imaging, PET/CT, radiotracer, scan | 3 Comments »
